Detailed Narrative
Global and Domestic AgChem Market Dynamics
The global crop protection market continued its multi-year downcycle, characterized by uneven recovery and a shift towards just-in-time purchasing. The conflict in the Middle East further added to disruptions. Domestically, while fundamentals are encouraging, near-term demand was muted due to elevated channel inventory, lower crop prices, and incessant rainfall, though the Rabi season was positive. Management expects growth momentum to pick up with a stronger Kharif season.
FY26 Financial Performance Overview
For the full year FY26, PI Industries delivered a consolidated revenue of ₹6,713.7 crores with healthy EBITDA margins of 25%. Gross margins expanded to 58% for the year, supported by a favorable product mix and strong operational efficiencies. The effective tax rate (ETR) for FY26 was 22%, with expectations to inch up to 24% in FY27 and thereafter. The company maintained a strong cash balance of ₹3,426.5 crores and a debt-free balance sheet.
Strategic Growth Pillars: Pharma, Biologicals, NCEs, and Electronic Chemicals
The Pharma business demonstrated robust growth of 40% for FY26, driven by onboarding strategic customers and building CRDMO capabilities. Global Biologicals, a segment with over 20%+ CAGR, is expanding with new product launches like a novel nematode in the US. The company is also focusing on its in-house New Chemical Entity (NCE) program, Pioxaniliprole, and entering Electronic Chemicals, targeting $100 million in revenue in 4-5 years, with investments of around ₹500 crores.
Capital Allocation and Investment Strategy
PI Industries incurred approximately ₹2,600 crores in capex over the last three years, with ₹1,100 crores in FY26, including ₹91 crores for pharma. These investments are directed towards multi-year capacity ramp-ups, NCE development, and new business arenas, which inherently have longer gestation periods, impacting asset turns from 2.5x to 1.5x. For FY27, the company guides for a capex of ₹700-800 crores, with ongoing R&D spends of ₹50-100 crores for new NCEs.
Margin Outlook and Raw Material Volatility
While gross margins remained healthy at 58% for FY26, EBITDA margins compressed to 22% in Q4 FY26 from 27-28% at the start of the year. Management acknowledged significant volatility in raw material prices and supply chain challenges, making it difficult to provide specific margin guidance for FY27. The company's strategy is to manage these factors without compromising long-term trajectory, market share, and growth, focusing on volume and market share retention.
Contract Assets and Working Capital Management
Contract assets reduced from ₹1,000 crores in December 2025 to ₹700 crores in March 2026. Management indicated that contract assets would likely hover around the ₹500-700 crore range, given the business model and supply chain complexities. The company aims to maintain trade working capital at around 139 days of sales, balancing customer needs with inventory management in a volatile market.